Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nexalin Technology, Inc. - Warrant
(NQ:
NXLIW
)
0.1672
UNCHANGED
Streaming Delayed Price
Updated: 2:22 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
52
Open
0.1672
Bid (Size)
0.0800 (10)
Ask (Size)
0.1631 (1)
Prev. Close
0.1672
Today's Range
0.1672 - 0.1672
52wk Range
0.0075 - 0.5600
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
April 25, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
April 09, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Performance
YTD
+2129.33%
+2129.33%
1 Month
+318.00%
+318.00%
3 Month
+1572.00%
+1572.00%
6 Month
+1094.29%
+1094.29%
1 Year
+30.12%
+30.12%
More News
Read More
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
April 04, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
April 02, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
March 28, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
March 14, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
March 13, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
March 06, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 08, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 23, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 11, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
December 18, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
October 25, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 16, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 07, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 03, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 26, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
June 01, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
January 24, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
January 05, 2023
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
November 14, 2022
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.